• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CoronaVac® 疫苗和自然感染诱导的抗体对野生型和 Alpha SARS-CoV-2 变异株的中和作用。

Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVac® Vaccine and Natural Infection- Induced Antibodies.

机构信息

Department of Medical Microbiology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.

Department of Medical Microbiology, Bezmialem Vakıf University Faculty of Medicine, Istanbul, Turkey.

出版信息

Curr Microbiol. 2023 Apr 1;80(5):162. doi: 10.1007/s00284-023-03248-6.

DOI:10.1007/s00284-023-03248-6
PMID:37004596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10066983/
Abstract

One of the immune responses desired to be achieved by SARS-CoV-2 vaccination is to create neutralizing antibodies (nAbs), thus preventing the development and spread of infection. The aim of this study was to investigate the seropositivity rate, anti-spike antibody levels, and neutralizing capacity of these antibodies against wild type (WT) and alpha variants in serum samples of individuals who had been naturally infected or vaccinated with CoronaVac®. Total anti-spike antibody levels were determined in all samples. Neutralization assays were performed by the reduction of the cytopathic effect in Vero-E6 cells with infectious WT and alpha SARS-CoV-2 variants. Although both naturally infected and vaccinated individuals were all seropositive for antispike antibodies, 84.8% of the vaccinated group, and 89.3% of the naturally infected group had detectable nAbs. The nAbs titers were significantly higher in the naturally infected group for both WT and alfa variant of the virus as compared to the vaccinated individuals. In this study, it was observed that all individuals became seropositive six weeks after exposure to the vaccine or the virus. Moreover, naturally infected individuals had higher levels of nAbs than those vaccinated. The presence of nAbs against the alpha variant in both naturally infected and vaccinated individuals suggests that these antibodies may also be protective against infections, which may be caused by other variants, such as delta and omicron.

摘要

接种 SARS-CoV-2 疫苗所期望产生的免疫反应之一是产生中和抗体(nAbs),从而防止感染的发生和传播。本研究旨在调查自然感染或接种科兴疫苗的个体血清样本中针对野生型(WT)和 alpha 变异株的血清阳性率、抗刺突抗体水平和这些抗体的中和能力。所有样本均测定了总抗刺突抗体水平。通过用具有传染性的 WT 和 alpha SARS-CoV-2 变异株降低 Vero-E6 细胞的细胞病变效应来进行中和测定。尽管自然感染和接种疫苗的个体均对抗刺突抗体呈血清阳性,但接种组中有 84.8%,自然感染组中有 89.3%的个体可检测到 nAbs。与接种个体相比,自然感染组针对 WT 和 alfa 变异株的 nAbs 滴度明显更高。在这项研究中,观察到所有个体在接触疫苗或病毒六周后均呈血清阳性。此外,自然感染个体的 nAbs 水平高于接种个体。自然感染和接种个体中均存在针对 alpha 变异株的 nAbs 表明,这些抗体也可能对其他变异株(如 delta 和 omicron)引起的感染具有保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3a/10066983/682938d20b60/284_2023_3248_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3a/10066983/682938d20b60/284_2023_3248_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3a/10066983/682938d20b60/284_2023_3248_Fig1_HTML.jpg

相似文献

1
Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVac® Vaccine and Natural Infection- Induced Antibodies.CoronaVac® 疫苗和自然感染诱导的抗体对野生型和 Alpha SARS-CoV-2 变异株的中和作用。
Curr Microbiol. 2023 Apr 1;80(5):162. doi: 10.1007/s00284-023-03248-6.
2
Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.新型冠状病毒肺炎进展:康复期血清中和抗体的持久性、有效性及免疫逃逸
Pathogens. 2022 Dec 13;11(12):1531. doi: 10.3390/pathogens11121531.
3
Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China.评价健康人群接种新冠病毒灭活疫苗(科兴中维)后的抗体动力学和持久性:中国浙江的一项横断面和队列研究。
Elife. 2023 Mar 16;12:e84056. doi: 10.7554/eLife.84056.
4
Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects.血清抗 SARS-CoV-2 中和抗体与 COVID-19 轻症/症状患者和接种疫苗者的活病毒中和试验滴度的关系。
Int Immunopharmacol. 2021 Dec;101(Pt B):108215. doi: 10.1016/j.intimp.2021.108215. Epub 2021 Oct 4.
5
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.CoronaVac 疫苗诱导的抗体对 alpha、gamma 和 D614G SARS-CoV-2 变异株的中和作用。
J Med Virol. 2022 Jan;94(1):399-403. doi: 10.1002/jmv.27310. Epub 2021 Sep 8.
6
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.恢复期和接种疫苗血清对 SARS-CoV-2 原始株、Beta、Delta 和奥密克戎变异株临床分离株的免疫原性。
Med. 2022 Jun 10;3(6):422-432.e3. doi: 10.1016/j.medj.2022.04.002. Epub 2022 Apr 14.
7
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.加强剂对康复的 COVID-19 患者血清中和针对奥密克戎变异株的活性:BNT162b2 和科兴疫苗的效果。
EBioMedicine. 2022 May;79:103986. doi: 10.1016/j.ebiom.2022.103986. Epub 2022 Apr 8.
8
Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.恢复期血浆捐献者在免疫接种后对 SARS-CoV-2 的抗原变异体表现出增强的交叉反应性中和抗体反应。
Transfusion. 2022 Jul;62(7):1347-1354. doi: 10.1111/trf.16934. Epub 2022 Jun 2.
9
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.mRNA 疫苗接种后针对 SARS-CoV-2 变体 RBD 的中和抗体反应减弱和异质性。
Front Immunol. 2022 Apr 6;13:816389. doi: 10.3389/fimmu.2022.816389. eCollection 2022.
10
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.骨髓瘤患者接种 SARS-CoV-2 疫苗后中和抗体反应的决定因素。
J Clin Oncol. 2022 Sep 10;40(26):3057-3064. doi: 10.1200/JCO.21.02257. Epub 2022 Mar 8.

引用本文的文献

1
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.严重急性呼吸综合征冠状病毒2的进化:对诊断、治疗、疫苗有效性及研发的影响
Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.
2
The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation.初始免疫抑制对肾移植患者接种SARS-CoV-2疫苗后体液反应动力学的影响。
Vaccines (Basel). 2024 Oct 3;12(10):1135. doi: 10.3390/vaccines12101135.

本文引用的文献

1
Overview of Neutralizing Antibodies and Their Potential in COVID-19.中和抗体及其在新冠病毒肺炎中的潜力概述
Vaccines (Basel). 2021 Nov 23;9(12):1376. doi: 10.3390/vaccines9121376.
2
Evaluation of antibody response after COVID-19 vaccination of healthcare workers.评价医护人员接种 COVID-19 疫苗后的抗体反应。
J Med Virol. 2022 Mar;94(3):1060-1066. doi: 10.1002/jmv.27420. Epub 2021 Nov 1.
3
[Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
[医护人员接种新型冠状病毒灭活疫苗后副作用、血清转化率及抗体反应的影响因素]
Mikrobiyol Bul. 2021 Oct;55(4):519-538. doi: 10.5578/mb.20219705.
4
Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.医护人员接种两剂灭活病毒疫苗后的免疫原性:有和无既往 COVID-19 感染的前瞻性观察研究。
J Med Virol. 2022 Jan;94(1):279-286. doi: 10.1002/jmv.27316. Epub 2021 Sep 10.
5
Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay.罗氏 Elecsys 抗 SARS-CoV-2 S 免疫分析的性能评估。
J Virol Methods. 2021 Nov;297:114271. doi: 10.1016/j.jviromet.2021.114271. Epub 2021 Aug 27.
6
Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.CoronaVac 疫苗诱导的抗体对 alpha、gamma 和 D614G SARS-CoV-2 变异株的中和作用。
J Med Virol. 2022 Jan;94(1):399-403. doi: 10.1002/jmv.27310. Epub 2021 Sep 8.
7
CoronaVac induces lower neutralising activity against variants of concern than natural infection.与自然感染相比,科兴新冠疫苗对变异株的中和活性较低。
Lancet Infect Dis. 2021 Oct;21(10):1352-1354. doi: 10.1016/S1473-3099(21)00568-5. Epub 2021 Aug 26.
8
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.一种灭活全病毒 SARS-CoV-2 疫苗(克尔来福)的有效性和安全性:在土耳其进行的一项双盲、随机、安慰剂对照、3 期临床试验的中期结果。
Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
9
Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil.巴西科兴新冠疫苗接种者中两例接种后感染 P1 变异株的 SARS-CoV-2 病例研究。
Viruses. 2021 Jun 26;13(7):1237. doi: 10.3390/v13071237.
10
Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 with grinch.利用“圣诞怪杰”追踪严重急性呼吸综合征冠状病毒2(SARS-CoV-2)谱系B.1.1.7和B.1.351/501Y-V2的国际传播情况
Wellcome Open Res. 2021 Sep 17;6:121. doi: 10.12688/wellcomeopenres.16661.2. eCollection 2021.